Omnihealth Practice

Twice yearly lenacapavir demonstrates remarkable efficacy in HIV prevention: Results from the phase 3 PURPOSE 1 trial

Despite the availability of once-daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) as a highly effective pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention, significant unmet needs remain.1,2 Many individuals, particularly adolescent girls and young women,

INFECTIOUS DISEASE

19 Sep 2024

Observational study highlights clinical characteristics and treatment patterns of patients with high-risk prostate cancer in Asia-Pacific

Patients with high-risk localized prostate cancer (HR LPC) are at significant risk of developing systemic or local recurrence as well as symptoms and/or death from the disease.1 While there is a range of treatment options available, including radical prostatectomy (RP), radiation therapy with or wit

ONCOLOGY UROLOGY

25 Aug 2024

“Plants for Joints” lifestyle intervention continues to show long-term benefits in osteoarthritis

The Plants for Joints (PFJ) study is a randomized controlled trial (RCT) in which 64 patients with hip and/or knee osteoarthritis (OA) with metabolic syndrome were randomized 1:1 to receive the PFJ intervention in addition to usual care, or a waitlist control group which received usual care.1 The PF

RHEUMATOLOGY

12 Sep 2024

Redefining the management of non-muscle-invasive bladder cancer in one swoop with en bloc resection over standard transurethral resection

Bladder cancer is one of the most prevalent cancers worldwide, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75% of bladder cancer cases. While the standard piecemeal transurethral resection of bladder tumor (SR) has been the conventional surgical procedure for NMIBC, oncological control remains subpar, prompting the development of alternative techniques such as en bloc transurethral resection of bladder tumor (ERBT). To examine the impact of ERBT on the prognosis of NMIBC, Professor Teoh, Yuen-Chun Jeremy and his team conducted a local phase 3 randomized controlled trial, EB-StaR, that compared the 1-year recurrence rate of NMIBC with ERBT to SR. In an interview with Omnihealth Practice, Prof. Teoh discussed the implications of the results and the future of ERBT implementation.

ONCOLOGY UROLOGY

06 Aug 2024

Professor Teoh, Yuen-Chun Jeremy

Associate Professor,
Department of Surgery,
Faculty of Medicine,
The Chinese University of Hong Kong

Emphasizing HAE diagnosis and management in the Asia-Pacific region with SHARP guidance

Hereditary angioedema (HAE) is a rare, yet potentially life-threatening, inheritable disease characterized by episodic attacks of cutaneous and submucosal swelling.1,2 Unfortunately, the adoption and implementation of international guidelines established in Asia-Pacific (AP) populations remains limi

08 May 2024

Professor Li, Hei Philip

Clinical Assistant Professor,
Division Chief of Rheumatology & Clinical Immunology,
Department of Medicine,
The University of Hong Kong

EULAR 2024

June 12-15, 2024 | Vienna, Austria

Validation of IMACS guidelines for enhanced cancer screening: A Hong Kong myositis cohort

Patients with adult-onset idiopathic inflammatory myopathy (IIM) are at increased risk of cancers.1 Recently, the International Myositis Assessment and Clinical Studies Group (IMACS) published recommendations on cancer risk stratification and screening for IIM patients.1 These include risk stratific

RHEUMATOLOGY

31 Jul 2024

New insights on the impact of tapering GCs or immunosuppressive therapy on damage accrual after achieving LLDAS and complete remission SLE

Systemic lupus erythematosus (SLE) is a lifelong disease with a median onset age of 15-44 years.1 As continued treatment with glucocorticoids (GCs) and immunosuppressive therapies can contribute to damage accrual, tapering of treatment is inevitable during the course of the disease.1 However, this c

RHEUMATOLOGY

02 Aug 2024

ASCO 2024

May 31-Jun 4, 2024 | Chicago, United States

Phase 3 PhALLON trial reveals high rates of MRD negativity at any time and prolonged PFS with ponatinib in patients with newly diagnosed Ph+ ALL

STUDY DESIGN Ponatinib is a third-generation BCR::ABL tyrosine kinase inhibitor (TKI) that inhibits BCR::ABL1 regardless of any single resistance mutations, including T315I. It was previously evaluated in the PhALLCON (ponatinib-3001) trial in adults with newly diagnosed Philadelphia chromosome-po

HEMATOLOGY ONCOLOGY

12 Sep 2024

Improved outcomes with FLOT perioperative chemotherapy vs. CROSS neoadjuvant chemoradiation for esophageal cancer: The ESOPEC Trial

The incidence of esophageal adenocarcinoma (EAC) is increasing, particularly in high-income countries, with almost 86,000 new cases globally in 2020.1 While surgery is the mainstay for cure in non-metastatic disease, multimodality treatment can improve survival in these patients.1 For early-stage tu

GASTROENTEROLOGY & HEPATOLOGY

05 Aug 2024

Twice yearly lenacapavir demonstrates remarkable efficacy in HIV prevention: Results from the phase 3 PURPOSE 1 trial

INFECTIOUS DISEASE

19 Sep 2024

FDA approval of dupilumab as EoE treatment expands to include pediatric patients aged ≥1 year

Earlier this year, the United States (US) Food and Drug Administration (FDA) expanded the approval of dupilumab to include the treatment of eosinophilic esophagitis (EoE) in pediatric patients aged ≥1 year weighing at least 15 kg.1 This decision was based on the significant improvements in various k

GASTROENTEROLOGY & HEPATOLOGY PEDIATRICS

21 Aug 2024

Local real-world evidence supports statin use in older adults aged ≥75 years for CVD prevention

Cardiovascular disease (CVD) is a leading healthcare burden and cause of mortality globally.1,2 The elderly are particularly at risk but are underrepresented in randomized controlled trials (RCTs) evaluating lipid-lowering drugs such as statins.1,3 As such, despite the recommendation for statin use

CARDIOLOGY

21 Aug 2024

Lasting protection from recurrence: A case sharing of high-risk HR+ HER2- EBC management with abemaciclib

Abemaciclib was the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to demonstrate a significant improvement in invasive disease-free survival (IDFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).¹ In an interview with Omnihealth Practice, Dr. Hui, Cheng-Vai cited data from large-scale clinical trials including monarchE, describing the long-term efficacy and tolerable safety profile of the 2-year fixed-duration abemaciclib treatment, even in populations who had received dose reductions. Dr. Sumou, Ingrid Karmane also shared her experience using abemaciclib in a case of an HR+ HER2- EBC patient with a high risk of recurrence, outlining the efficacy of the treatment and how its tolerability profile can be managed. Additionally, they highlighted the importance of patient education and close follow-up by a multi-disciplinary team to enhance treatment outcomes.

ONCOLOGY OBSTETRICS & GYNECOLOGY

20 Sep 2024

Dr. Hui, Cheng-Vai

Consultant in Medical Oncology,
Macau Oncology Association

Dr. Sumou, Ingrid Karmane

Medical Oncologist,
Macau Oncology Association

Sequencing retreatment with anti-CD38 mAb in heavily pretreated RRMM patients

Patients with multiple myeloma (MM) are highly susceptible to developing relapsed and refractory (RR) disease towards lenalidomide and proteasome inhibitors (PIs) and require new active treatments at relapse. As such, novel treatment options like isatuximab, a monoclonal antibody (mAb) that targets

HEMATOLOGY

06 Mar 2024

Professor Yong, Kwee

University College London,
United Kingdom

Every update. In your inbox.

Get access to our exclusive articles.

Overseeing local ocular health with a watchful gaze: Consensus on managing center-involving DME in Hong Kong

Diabetic macular edema is a prevalent cause of vision loss among individuals in the working-age population, characterized by the disruption of the blood-retinal barrier and the accumulation of fluid and serum macromolecules in the intercellular space. As the incidence of diabetes mellitus

OPHTHALMOLOGY

02 Jul 2024

Refining the management of hyperkalemia in the Asia-Pacific region: Consensus statements from a multidisciplinary expert panel

Hyperkalemia, defined as serum potassium >5.0mmol/L, is a potentially lethal condition as it hinders muscle function and myocardial excitability, which may contribute to arrhythmias and sudden cardiac deaths. Epidemiological data suggests the global prevalence of hyperkalemia is around 6.3%, but the

NEPHROLOGY

20 Jun 2024

Nephrology. 2024

Yap YHD, Ma CWR, Wong CKE, Tsui SHM, Yu YTE, Yu V, Szeto CC, Pang WF, Tse HF, Siu CDW, Tan CBK, Chen WCW, Li CL, Chen W, Chan TM. Consensus statement on the management of hyperkalaemia—An Asia-Pacific perspective. Nephrology. 2024;29(6):311-324.

Case sharing: Improving treatment outcome in MDD patients with timely brexpiprazole augmentation

Treatment-resistant depression (TRD) is defined as treatment failure following ≥2 trials of antidepressant therapy (ADT) at adequate doses, duration and adherence.1 Around 30% of patients with major depressive disorder (MDD) become resistant to conventional treatments.2 TRD is independently associa

PSYCHIATRY

09 May 2024

Dr. Lai, Chi-Lun

Specialist in Psychiatry

Case sharing: Brexpiprazole augmentation in MDD patients with anxiety symptoms provides the trifactor of clinical outcomes, patient compliance and functional recovery

Among patients suffering from major depressive disorder (MDD), more than half of them are encumbered with comorbid anxiety symptoms.1 They represent a more severe form of depression and are often associated with higher morbidity.2 Recovery is more difficult due to a reduced likelihood of response to

PSYCHIATRY

13 Mar 2024

Dr. Tso, Kwok-Chu

Specialist in Psychiatry

Exploring TYK2-targeted approaches: Deucravacitinib demonstrates notable efficacy and tolerability as a first-in-class treatment for psoriasis

DERMATOLOGY

02 Aug 2024

Dr. Linda Stein Gold

Director of Dermatology Clinical Research,
Henry Ford Health System,
Detroit, United States

Reshaping CLL care: Acalabrutinib-based regimens at the forefront of CLL management

HEMATOLOGY

09 May 2024

Dr. Jeff Sharman

Willamette Valley Cancer Institute and Research Center,
Eugene, United States

Infographics

OPHTHALMOLOGY NEPHROLOGY

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

21 Jun 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024

NEUROLOGY

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

HEMATOLOGY

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024

NEUROLOGY

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

HEMATOLOGY CARDIOLOGY

Incidence of anemia with long-term low-dose aspirin

18 Mar 2024

Decoding the spectrum of tolerance in fish allergies

04 Jan 2024

DIABETES & ENDOCRINOLOGY CARDIOLOGY

Earlier and higher risk of CVD with a younger T2D diagnosis

04 Jan 2024

DIABETES & ENDOCRINOLOGY

U-shaped relationship between sleep duration and T2DM regardless of traditional lifestyle risk factors

17 Nov 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

DIABETES & ENDOCRINOLOGY NEUROLOGY

The nuanced link between prediabetes and dementia

23 Aug 2023

NEUROLOGY RHEUMATOLOGY

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

CARDIOLOGY PEDIATRICS

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

RESPIROLOGY

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

HEMATOLOGY PEDIATRICS

A new way out for alpha thalassemia major - Give them a chance at life with In-utero transfusions

15 Mar 2023

RESPIROLOGY

Beware of overlapping phenotypes in severe asthma: The eosinophilia and IgE double whammy

27 Feb 2023

NEPHROLOGY

Stay on the path of treatment - Take on a high-K with ease
ASN abstract highlight on sodium zirconium cyclosilicate and hyperkalemia

23 Feb 2023

RESPIROLOGY

Real-world effectiveness of benralizumab around the globe

06 Dec 2022

RESPIROLOGY

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

ONCOLOGY RESPIROLOGY

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC